Acute coronary syndrome (ACS)─an umbrella term that encompasses acute ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina─is a leading cause of morbidity and mortality in the developed world. We focus on two specific settings in the treatment of ACS: the acute hospital setting and the 12-month posthospital setting in the seven major pharmaceutical markets we cover (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). In the acute setting, where injectable anticoagulants, thrombolytics, and glycoprotein (gp) IIb/IIIa inhibitors dominate, the market is set to suffer a decline in sales due to the generic erosion of key brands and a lack of novel drugs launching. The 12-month posthospital ACS market, which is dominated by oral antiplatelet agents, is currently seen by drug developers as a potentially more-lucrative source of sales compared with the acute setting. Indeed, this market is set to see the launch of ten add-on or replacement therapies during the forecast period.

Questions Answered:

  • What are the drivers and constraints in the acute and 12-month posthospital ACS markets, and how will these markets evolve over the forecast period?
  • What is the current state of treatment in ACS? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
  • What are thought leaders’ opinions of the prospects of the ten add-on and replacement therapies that are set to launch through 2026 in the post-hospital ACS population?
  • How will the anticipated launches of novel lipid-targeting therapies, including Sanofi/Regeneron’s Praluent, Amgen's Repatha, The Medicines Company/Alnylam Pharmaceuticals’ inclisiran, Esperion Therapeutics’ bempedoic acid, Resverlogix’s apabetalone, and Dalcor’s dalcetrapib, affect the treatment of ACS patients in the posthospital setting? What level of market penetration can we expect of these therapies given the increasingly crowded and competitive landscape?

Product Description:

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Acute Coronary Syndrome - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Dominika Rudnicka-Noulin

Dominika Rudnicka-Noulin, PhD, MSc is a senior business insights analyst in the Cardiovascular, Metabolic and Renal division at Decision Resources Group, specializing in cardiovascular diseases, with expertise in heart failure and acute coronary syndrome.

Prior to joining DRG, Dominika held a position of an associate editor at Nature Communications, working across a variety of therapy areas. Dominika also worked for three years as a Postdoctoral Research Associate on a joint project between Imperial College London and MedImmune aimed at developing more potent antibody-based drugs. Dominika gained her PhD at the Institut Pasteur in Paris, France where her work was funded by the European Commission Marie Skłodowska-Curie Actions